Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics


Arcus Biosciences, Inc. (RCUS)

Today's Latest Price: $25.47 USD

0.19 (0.75%)

Updated Jul 9 6:40pm

Add RCUS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

RCUS Stock Summary

  • For RCUS, its debt to operating expenses ratio is greater than that reported by only 0.34% of US equities we're observing.
  • With a price/sales ratio of 77.6, Arcus Biosciences Inc has a higher such ratio than 97.05% of stocks in our set.
  • The volatility of Arcus Biosciences Inc's share price is greater than that of 94.9% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Arcus Biosciences Inc, a group of peers worth examining would be VBLT, ATHX, NTLA, DTIL, and WVE.
  • Visit RCUS's SEC page to see the company's official filings. To visit the company's web site, go to www.arcusbio.com.
RCUS Daily Price Range
RCUS 52-Week Price Range

RCUS Stock Price Chart Technical Analysis Charts


RCUS Price/Volume Stats

Current price $25.47 52-week high $37.41
Prev. close $25.28 52-week low $6.30
Day low $24.74 Volume 428,600
Day high $25.97 Avg. volume 610,967
50-day MA $28.69 Dividend yield N/A
200-day MA $16.01 Market Cap 1.17B

Arcus Biosciences, Inc. (RCUS) Company Bio


Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.


RCUS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

RCUS Latest Social Stream


Loading social stream, please wait...

View Full RCUS Social Stream

Latest RCUS News From Around the Web

Below are the latest news stories about Arcus Biosciences Inc that investors may wish to consider to help them evaluate RCUS as an investment opportunity.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 190,200 shares of the Company’s common stock at an exercise price per share of $25.28, which was the closing price on July 8, 2020. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

Yahoo | July 9, 2020

Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020. Mr. Goeltz is a proven financial leader with substantial operational experience in both large and small cap biopharmaceutical company environments. “Following the recent announcement of our 10-year collaboration with Gilead and successful

Business Wire | July 7, 2020

Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?

Is (RCUS) Outperforming Other Medical Stocks This Year?

Yahoo | June 29, 2020

Arcus Biosciences (RCUS) Investor Presentation - Slideshow

The following slide deck was published by Arcus Biosciences, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | June 23, 2020

Hedge Funds Have Never Been This Bullish On Arcus Biosciences, Inc. (RCUS)

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

Yahoo | June 17, 2020

Read More 'RCUS' Stories Here

RCUS Price Returns

1-mo -14.07%
3-mo N/A
6-mo 153.69%
1-year 198.94%
3-year N/A
5-year N/A
YTD 152.18%
2019 -6.22%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching RCUS

Want to see what other sources are saying about Arcus Biosciences Inc's financials and stock price? Try the links below:

Arcus Biosciences Inc (RCUS) Stock Price | Nasdaq
Arcus Biosciences Inc (RCUS) Stock Quote, History and News - Yahoo Finance
Arcus Biosciences Inc (RCUS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8306 seconds.